Frost & Sullivan Independent Equity Research
DNA. Entera is now trading under NASDAQ:ENTX; Entera has completed Part 1 of a Phase 2 PK/PD Study in Hypoparathyroidism; BeamMed posted impressive revenue growth, with a strategic focus on the US; target price increased by 50% to NIS 1.19.
Company: DNA Biomedical Solutions, Ltd.
Report type: Q2-2018 Update & 12 Months Since Initiation of Coverage
Published on: 12 September, 2018